Cowen Starts Oyster Point Pharma (OYST) at Outperform, Street High $40 PT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Cowen Starts Oyster Point Pharma (OYST) at Outperform, Street High $40 PT
November 25, 2019 5:50 AM EST
Oyster Point Pharma, Inc. (NASDAQ: OYST) announced the positive top-line results from its Phase 1 ZEN study in healthy volunteers. The ZEN Study was an open-label, single-center, randomized, 2-way crossover study to evaluate the relative bioavailability of varenicline administered as a preservative-free nasal spray (OC-01 nasal spray) as compared to varenicline administered orally as a single oral dose of Chantix®.
The ZEN study was designed to assess the relative bioavailability of varenicline administered intranasally at its highest intended clinical strength (1.2 mg/ml in a 50 microliter nasal spray) compared to varenicline... More
November 25, 2019 4:15 AM EST
JPMorgan analyst Oyster Point Pharma initiates coverage on Oyster Point Pharma (NASDAQ: OYST) with a Overweight rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Oyster Point Pharma... More
November 25, 2019 4:14 AM EST
Piper Jaffray analyst Tyler Van Buren initiates coverage on Oyster Point Pharma (NASDAQ: OYST) with a Overweight rating and a price target of $35.00.
For an analyst ratings summary and ratings history on Oyster Point Pharma... More
